(Q24244087)

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

High-dose epirubicin is not an alternative to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study of the EORTC soft tissue and bone sarcoma group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

Cardiotoxicity of cancer chemotherapy: implications for children

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

A clinicopathologic analysis of adriamycin cardiotoxicity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Randomized study comparing 4'-epi-doxorubicin (epirubicin) versus doxorubicin as a part of induction treatment in adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Comparison of epirubicin and doxorubicin cardiotoxicity induced by low doses: evolution of the diastolic and systolic parameters studied by radionuclide angiography

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Treatment of advanced ovarian cancer: a randomised trial comparing adriamycin or 4'epi-adriamycin in combination with cisplatin and cyclophosphamide

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Results of a randomized study of early stage Hodgkin's disease using ABVD, EBVD, or MBVD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

A randomized comparison of the efficacy and toxicity of epirubicin and doxorubicin in the treatment of patients with non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4'-epi-doxorubicin in the treatment of advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

New anthracycline analogs in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Combination chemotherapy including epirubicin for the management of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

New anthracycline antitumor antibiotics

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Cardiac toxicity of daunorubicin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Combining platinum, paclitaxel and anthracycline in patients with advanced gynaecological malignancy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Anticancer agents and cardiotoxicity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Improved treatment results in children with AML: Results of study AML-BFM 93

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

[Therapy realization and complications in the BFM-83 therapy study of acute myelogenous leukemia]

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. A multicenter trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Cardiotoxicity of epirubicin and doxorubicin: a double-blind randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Evaluation of long term cardiotoxicity after epirubicin containing adjuvant chemotherapy and locoregional radiotherapy for breast cancer using various detection techniques.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

5-Fluorouracil, adriamycin, cyclophosphamide (FAC) vs. 5-fluorouracil, epirubicin, cyclophosphamide (FEC) in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Phase III randomized study of fluorouracil, epirubicin, and cyclophosphamide v fluorouracil, doxorubicin, and cyclophosphamide in advanced breast cancer: an Italian multicentre trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Doxorubicin and 4'-epidoxorubicin in combination chemotherapy of extensive small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Late cardiac toxicity of doxorubicin, epirubicin, and mitoxantrone therapy for Hodgkin's disease in adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Phase III comparative trial using CHOP vs CIOP in the treatment of advanced intermediate-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Long-term results of combined-modality therapy for inflammatory breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021

Anthracycline-induced cardiotoxicity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005006.PUB2

7 January 2021